Lichen China Limited (NASDAQ:LICN – Get Free Report) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 91,000 shares, a decline of 16.9% from the October 15th total of 109,500 shares. Approximately 0.4% of the company’s shares are sold short. Based on an average trading volume of 352,300 shares, the days-to-cover ratio is presently 0.3 days.
Institutional Investors Weigh In On Lichen China
A hedge fund recently bought a new stake in Lichen China stock. XTX Topco Ltd bought a new position in Lichen China Limited (NASDAQ:LICN – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 37,315 shares of the company’s stock, valued at approximately $54,000. XTX Topco Ltd owned 0.14% of Lichen China at the end of the most recent quarter.
Lichen China Trading Up 4.4 %
Shares of LICN stock opened at $1.88 on Monday. Lichen China has a twelve month low of $0.50 and a twelve month high of $2.44. The stock has a fifty day simple moving average of $1.89 and a two-hundred day simple moving average of $1.76.
About Lichen China
Lichen China Limited, together with its subsidiaries, operates as an investment holding company, provides financial and taxation, education support, and software and maintenance services in the People's Republic of China and internationally. The company offers financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation services; and education support services, including marketing, operational, and technical support, as well as sells teaching and learning materials.
Featured Articles
- Five stocks we like better than Lichen China
- How to Invest in Small Cap StocksĀ
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- Overbought Stocks Explained: Should You Trade Them?
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- Learn Technical Analysis Skills to Master the Stock Market
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Lichen China Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lichen China and related companies with MarketBeat.com's FREE daily email newsletter.